Copyright
©The Author(s) 2023.
World J Gastroenterol. Jul 7, 2023; 29(25): 3964-3983
Published online Jul 7, 2023. doi: 10.3748/wjg.v29.i25.3964
Published online Jul 7, 2023. doi: 10.3748/wjg.v29.i25.3964
Table 1 Efficacy of available antiviral treatments and nucleos(t)ide analogues withdrawal to achieve hepatitis B virus surface antigen loss
Ref. | Treatment (duration) | HBeAg | Ethnicity | Follow-up | HBsAg loss (%) |
Current antiviral treatments | |||||
Lau et al[84], 2005 | Peg-IFNα (1 yr) | + | Mainly Asian | 6 mo | 2.9 |
Marcellin et al[85], 2013 | Peg-IFNα (1 yr) | - | Asian | 60 mo | 12.0 |
Chang et al[48], 2010 | ETV (5 yr) | + | Asian | - | 1.4 |
Ahn et al[32], 2016 | ETV (5 yr) | - | Mixed | - | 4.6 |
Marcellin et al[33], 2019 | TDF (10 yr) | + | Mixed | - | 4.9 |
Marcellin et al[33], 2019 | TDF (10 yr) | - | Mixed | - | 3.4 |
Chan et al[30], 2016 | TAF (3 yr) | + | Mixed | - | 4.0 |
Buti et al[31], 2016 | TAF (3 yr) | - | Mixed | - | 3.0 |
Combined treatments | |||||
Marcellin et al[86], 2016 | Peg-IFN + TDF (1 yr) | +/- | Mixed | 18 mo | 9.1 |
Bourlière et al[87], 2017 | ETV, TDF, ADV, and LAM (1 yr) | - | Caucasian | 12 mo | 7.8 |
Lim et al[88], 2022 | NA add-on Peg-IFN (1 yr) | +/- | Asian | 6 mo | 12.1 |
Mo et al[89], 2022 | NAs (HBsAg < 1500 IU/mL, 1 yr) | - | Asian | 48 mo | 33.2 |
Lim et al[88], 2022 | NA switch to Peg-IFN (1 yr) | +/- | Asian | 6 mo | 9.7 |
NA discontinuation | |||||
Chen et al[90], 2018 | 2.7 yr | + | Asian | 96 mo | 19.6 |
Song et al[91], 2021 | 2.9 yr | + | Asian | 73 mo | 9.5 |
Kuo et al[92], 2019 | 3.1 yr | + | Asian | 24 mo | 4.7 (ETV); 0 (TDF) |
Jeng et al[72], 2018 | 2.9 yr | - | Asian | 36 mo | 13 |
Chen et al[90], 2018 | 2.9 yr | - | Asian | 96 mo | 33.1 |
Kuo et al[92], 2019 | 3.1 yr | - | Asian | 36 mo | 10 (ETV); 15 (TDF) |
Chen et al[93], 2020 | 3.2 yr | - | Asian | 58 mo | 20.8 |
Song et al[91], 2021 | 2.7 yr | - | Asian | 73 mo | 14.6 |
Hirode et al[47], 2022 | 3.0 yr | - | Mixed | 17 mo | 15.0 |
- Citation: Broquetas T, Carrión JA. Past, present, and future of long-term treatment for hepatitis B virus. World J Gastroenterol 2023; 29(25): 3964-3983
- URL: https://www.wjgnet.com/1007-9327/full/v29/i25/3964.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i25.3964